The discovery and development of our first-in-class Hec1/Nek2 inhibitor, oral anti-cancer drug T-1101 (Tosylate), have been accepted for an oral presentation at the 19th Annual Congress of International Drug DiscoveryScience & Technology (IDDST-2023).
News
News
![](https://www.taivex.com/wp-content/uploads/2022/10/iStock-news.png)
![](https://www.taivex.com/wp-content/uploads/2022/10/橙圓元素.png)
T-1101 be invited for an oral presentation at the 19th Annual Congress of International Drug DiscoveryScience & Technology (IDDST-2023)
![](https://www.taivex.com/wp-content/uploads/2022/12/T-1301-1.png)
T-1101 be invited for an oral presentation at the 19th Annual Congress of International Drug DiscoveryScience & Technology (IDDST-2023)
![](https://www.taivex.com/wp-content/uploads/2022/10/pill-1.png)
![](https://www.taivex.com/wp-content/uploads/2022/10/pill-2-1.png)
![](https://www.taivex.com/wp-content/uploads/2022/10/pill-3.png)
![](https://www.taivex.com/wp-content/uploads/2022/10/pill-2.png)
![](https://www.taivex.com/wp-content/uploads/2022/10/pill-1-1.png)